Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase 11 (MAPK11), commonly known as p38β, is a serine/threonine kinase belonging to the p38 mitogen-activated protein kinase (MAPK) family. It plays a critical role in cellular responses to environmental stress, physical stimuli, and pro-inflammatory cytokines by phosphorylating downstream transcription factors and kinases. MAPK11 is ubiquitously expressed, with particularly high levels in the heart, brain, and skeletal muscle, where it regulates processes such as cell differentiation, apoptosis, and myogenesis. Dysregulation of MAPK11 signaling is implicated in various pathological conditions, including chronic inflammatory disorders, autoimmune diseases, neurodegenerative conditions like Huntington's disease, and several types of cancer.
Therapeutic targeting of MAPK11 has primarily focused on small-molecule inhibitors, many of which dual-target both the alpha (MAPK14) and beta isoforms due to high sequence similarity. While several p38 inhibitors, such as losmapimod and ralimetinib, have entered clinical trials for inflammatory diseases, neuropathic pain, and oncology, their clinical development has faced significant hurdles. Notable challenges include class-wide safety concerns such as hepatotoxicity, skin rashes, and central nervous system toxicities, alongside potential efficacy limitations stemming from functional redundancy with other p38 isoforms.
Inhibitor of p38 mitogen-activated protein kinase (MAPK), acting via ATP-competitive or allosteric binding to block downstream phosphorylation cascades.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase 11 (MAPK11).